×
IBio Operating Expenses 2010-2024 | IBIO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
IBio operating expenses from 2010 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
View More
IBio Operating Expenses 2010-2024 | IBIO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
IBio operating expenses from 2010 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$151.4B
Bristol Myers Squibb (BMY)
$119.8B
Gilead Sciences (GILD)
$119.1B
Vertex Pharmaceuticals (VRTX)
$113.7B
CSL (CSLLY)
$83.5B
Regeneron Pharmaceuticals (REGN)
$75.5B
GSK (GSK)
$72.7B
Argenex SE (ARGX)
$39.5B
Alnylam Pharmaceuticals (ALNY)
$35.3B
BioNTech SE (BNTX)
$29B
BeiGene (ONC)
$22.2B
Biogen (BIIB)
$21B
Illumina (ILMN)
$20.9B
Moderna (MRNA)
$15.7B
Incyte (INCY)
$14.2B
Insmed (INSM)
$14B
Intra-Cellular Therapies (ITCI)
$13.5B
Genmab (GMAB)
$13.1B
Genmab (GNMSF)
$12.9B
BioMarin Pharmaceutical (BMRN)
$12.1B
Bio-Techne Corp (TECH)
$11.4B
Vaxcyte (PCVX)
$11.1B
Sarepta Therapeutics (SRPT)
$11B
Exact Sciences (EXAS)
$10.2B
Swedish Orphan Biovitrum (BIOVF)
$10.1B
Bio-Rad Laboratories (BIO.B)
$10B
QIAGEN (QGEN)
$9.7B
Repligen (RGEN)
$9.5B
Exelixis (EXEL)
$9.4B
Roivant Sciences (ROIV)
$8.1B